RxDoctor Payments Data

Anthony Chen, MD

Internal Medicine · Hacienda Heights, CANPI 1073527099

Payments from drug & device makers

$688in general payments, 2019–2025

Across 41 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$159
  • Merck$156
  • Kowa Pharmaceuticals America, Inc.$107
  • Amgen$106
  • AbbVie$63
  • Lilly USA, LLC$40
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$67698%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$688 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$149,263
Medicare patients
165
Services billed
1,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin92$93,442
FarxigaDapagliflozin Propanediol101$86,573
JanuviaSitagliptin Phosphate61$60,607
EliquisApixaban15$18,469
CreonLipase/Protease/Amylase12$16,899
XareltoRivaroxaban16$13,886
Atorvastatin Calcium819$11,217
Rosuvastatin Calcium747$10,850
Raloxifene Hcl201$10,463
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide199$10,271
Febuxostat40$10,119
Ezetimibe289$9,904
MyrbetriqMirabegron13$8,293
Olmesartan Medoxomil334$7,034
Valsartan251$6,061

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$156$60,60761 claims
PfizerEliquis$159$18,46915 claims
AbbVieCreon$63$16,89912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hacienda Heights

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →